Previous 10 | Next 10 |
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at t...
Image source: The Motley Fool. Enanta Pharmaceuticals (NASDAQ: ENTA) Q1 2022 Earnings Call Feb 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2022 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Jennifer Viera - IR Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...
Enanta Pharma press release (NASDAQ:ENTA): Q1 GAAP EPS of -$1.48 misses by $0.37. Revenue of $27.65M (-12.9% Y/Y) beats by $0.28M. For further details see: Enanta Pharma GAAP EPS of -$1.48 misses by $0.37, revenue of $27.65M beats by $0.28M
Expects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month Completed Enrollment in RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Viru...
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2021 afte...
Plans to Initiate First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, in February 2022 Completes Enrollment for RSVP, a Phase 2 Study of EDP-938 in Community-Acquired Respiratory Syncytial Virus (RSV) Infec...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 40 th Annual J.P...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-r...
The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Enanta Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...